Up-regulated expression of type II very low density lipoprotein receptor correlates with cancer metastasis and has a potential link to β-catenin in different cancers

Table 3 Correlation between VLDLR II expression and clinical features in 46 Breast cancer patients

Parameters	Number	VLDLR II fold	P
Age at diagnosis
≥ 50 years	29	1.30 ± 0.44	0.820
< 50 years	17	1.28 ± 0.40
Body weight
≥ 50 kg	19	1.38 ± 0.39	0.080
< 50 kg	27	1.21 ± 0.43
TC
> 5.20 mmol/L	7	1.09 ± 0.34	0.178
≤ 5.20 mmol/L	39	1.31 ± 0.42
TG
> 1.70 mmol/L	13	1.15 ± 0.28	0.360
≤ 1.70 mmol/L	33	1.33 ± 0.45
Histological grade
Well to moderately differentiated	28	1.18 ± 0.36	0.043*
Poorly differentiated	18	1.43 ± 0.45
Tumor size
≥ 2 cm	21	1.34 ± 0.47	0.442
< 2 cm	25	1.22 ± 0.37
Lymph node metastasis
Negative	15	1.14 ± 0.15	0.003*
Positive	31	1.43 ± 0.45
Distant metastasis
Negative	32	1.16 ± 0.30	0.007*
Positive	14	1.52 ± 0.41
TNM stage
Stage I-II	24	1.14 ± 0.31	0.027*
Stage III-IV	22	1.41 ± 0.47

Folds (VLDLR II protein in tumor/in normal) in mean ± SD. VLDLR II measured by Western blot. TC, total cholesterol (normal range: ≤ 5.20 mmol/L); TG, triglycerides (normal range: ≤ 1.70 mmol/L). Statistical analyses were performed by Mann-Whitney test.
* P < 0.05 is considered significan

ISSN: 1471-2407